Q: Can you comment on Thomson Reuters quarter and guidance for next year Thank You
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Any reason for the price drop ?
Q: Hi 5i,
From your previous answers, you've like LLL in the past. Do you still like it? Does the upcoming merger change your views?
TIA!
From your previous answers, you've like LLL in the past. Do you still like it? Does the upcoming merger change your views?
TIA!
Q: Is Obsidian a take over prospect or is it heading to bankruptcy or?
Thanks Wayne
Thanks Wayne
Q: Hello
Could you comment on MOS earnings and give opinion?
From what I read they beat consensus estimates and offered good 2019 guidance but yet the stock is down 4 % today ?
Thank you
Stephane
Could you comment on MOS earnings and give opinion?
From what I read they beat consensus estimates and offered good 2019 guidance but yet the stock is down 4 % today ?
Thank you
Stephane
Q: May I have your thoughts on the CXI quarterly results? The market doesn't appear to be impressed.
With appreciation.
Ed
With appreciation.
Ed
Q: Hi, If my memory serves well, Mark Leonard transferred ownership of a company to his adult children, which owns 1,000,000 CSU shares, a few years ago. I believe that his current holding of 400,000 + shares is in addition to that family ownership? Thanks
Q: Please provide your top 5 non technology US stocks. Thanks
Q: When does Vermillion report there earnings?
Thanks Guys
Thanks Guys
Q: Can I get your thoughts and preference between CSCO and QCOM?
Q: I like this stock and noted your comments that it may not move a lot until later in the year. What do you think about a straddle for the next few months. Thanks
Q: Is there any news to account for the share price climb in Couche-Tard today? I am thinking about adding to my position now that it has broken its multi-year consolidation trend. Your thoughts please. Thanks.
Q: Please suggest an S&P 500 ETF and U.S. Dividend ETF that would be best served as a long term hold in a TFSA.
Thanks
Thanks
Q: I saw you response on their earnings.Stock gets slammed and now is right back up. Do i sell it? what about a switch maybe cigi Colliers
Q: I know the deadline for tax "loss" selling is late December, but I'm not sure about the date for stock "gain" selling in regards to 2018 tax purposes. Is it the same or a later date?
thanks,
Paul
thanks,
Paul
Q: Hi 5iR, Could the team give me your top three 5G and AI stock picks? I suspect these will all be US stocks, but hopefully there may be a few extra Canadian stocks to add to the list?? Thanks 5iR Team. Cheers, Chris
-
Bank of Nova Scotia (The) (BNS)
-
BCE Inc. (BCE)
-
Enbridge Inc. (ENB)
-
Sun Life Financial Inc. (SLF)
-
Brookfield Renewable Partners L.P. (BEP.UN)
-
Algonquin Power & Utilities Corp. (AQN)
-
Chartwell Retirement Residences (CSH.UN)
-
Alaris Equity Partners Income Trust (AD.UN)
-
Kinaxis Inc. (KXS)
-
A&W Revenue Royalties Income Fund (AW.UN)
-
Medical Facilities Corporation (DR)
Q: I have $25,000 in my TFSA invested in the above companies, eaqch with a weighing of between 8% - 10%. Looking to add another $10,000. I'm 63. Preference is dividends and some growth. Looking for stability if another December 2018 were to repeat itself.
May I please have your suggestions, in order of preference. Please deduct appropriate credits.
Thank you.
May I please have your suggestions, in order of preference. Please deduct appropriate credits.
Thank you.
Q: Hi, I received shares in this company (HLS) via a reverse takeover of ADM (Automodular) back in late '17.
I don't see any other questions on this company thus the inquiry. What is your valued opinion of HLS?
From their web page...'HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. '
They seem to have a couple of drugs Vascepa, Clozaril and Absorica that are or will generate decent revenues going forward.
They also introduced a quarterly dividend recently and I know you favour companies when this occurs.
Are they a 'show me' story right now and patience is required for a couple quarters to see how they proceed, ie it looks like they will be filing for approval with Health Canada in early 2019 for Vascepa (it's already FDA approved).
Analysts targets are for around $20 for 2019 (from your 'Companies' page).
Cheers,
Steve
I don't see any other questions on this company thus the inquiry. What is your valued opinion of HLS?
From their web page...'HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. '
They seem to have a couple of drugs Vascepa, Clozaril and Absorica that are or will generate decent revenues going forward.
They also introduced a quarterly dividend recently and I know you favour companies when this occurs.
Are they a 'show me' story right now and patience is required for a couple quarters to see how they proceed, ie it looks like they will be filing for approval with Health Canada in early 2019 for Vascepa (it's already FDA approved).
Analysts targets are for around $20 for 2019 (from your 'Companies' page).
Cheers,
Steve
Q: Hi, Could you tell me if XTR and MFT would compliment each other, or is there some or too much overlap between the two, or in other words is there much correlation, thanks?
Q: Is there any stock(s) out there US or CDN that showed up on your radar screen lately that you think has a good momentum but also it is not stratospheric levels? I have some money that i need to deploy but don't want to add to my current holdings.